Clinical Trial

Stereotactic Intracerebral Injection of IPSC-DAPs in Patients with Parkinson's Disease

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 12, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments primarily manage symptoms but do not halt or reverse neuronal loss. Cellular replacement therapy has emerged as a potential strategy to restore dopaminergic function and address the underlying neuronal deficits. This study aims to evaluate the safety, feasibility, and efficacy of transplanting dopaminergic neurons into the brain to improve motor function and quality of life in patients with advanced Parkinson's disease.
Trial Details
NCT Number NCT06821529
Lead Sponsor iCamuno Biotherapeutics Ltd.
Collaborators: Second Affiliated Hospital, Zhejiang University, School of Medicine
Conditions Parkinson Disease
Enrollment 12 participants
Start Date 2025-05-15
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-12